Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHLW (Japan) approved Omjjara (momelotinib) for the treatment of myelofibrosis – GSK

Written by | 2 Jul 2024

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Omjjara (momelotinib) for the treatment of myelofibrosis. Omjjara is a once-a-day, oral JAK1/JAK2 and… read more.

CHMP positive for Omjjara (momelotinib) to treat myelofibrosis – GSK

Written by | 14 Nov 2023

On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.

Ojjaara (momelotinib) approved by FDA to treat intermediate or high-risk myelofibrosis – GSK

Written by | 20 Sep 2023

GSK plc announced that the FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.